Spectrum Science acquires clinical trial recruitment and engagement solutions provider Continuum Clinical from marketing agency Blue Chip Worldwide. Details of the transaction were not disclosed.

Continuum will merge with Spectrum's existing clinical trial recruitment strategic pillar. Continuum president Neil Weisman will continue in his role, leading Spectrum's CTR strategic pillar and overseeing a combined team of more than 130 clinical solutions specialists.

The acquisition is intended to bolster Spectrum’s current offering by adding overall depth and breadth of capabilities, as well as bringing a large and diverse client roster.

Continuum also brings to the partnership its MERIS™ Total Engagement Solution—a suite of proprietary, globally compliant technology products designed to enable a seamless clinical trial experience for study participants and research sites, while producing real-time, actionable performance data for sponsors.

“Together our combined businesses make us one of the largest full-service recruitment providers in the industry,” said Spectrum Science CEO Jonathan Wilson. "Even more notably, our shared perspective on the importance of putting patients first, leading with strategic insights that result in bespoke solutions and leveraging proprietary technology to create more frictionless experiences for all stakeholders, has us primed to make transformational impact for our clients and for the future of clinical trials."